High Neuronal PAS Domain Protein 2 Expression Associated with Poor Prognosis, Tumor Immune Infiltration, and Adenosine Pathway Markers in Lung Cancer
Journal of Visualized Experiments · 05.11.2026 · (237)
DOI: 10.3791/74928 ↗Kurz gefasst
Video/Audio in der Zeitschrift Journal of Visualized Experiments, online erschienen am 05.11.2026. Verfasst von Jingjing Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University; hayydaijj@njmu.edu.cn. Hauptthemen laut MEDLINE: Lung Neoplasms, Basic Helix-Loop-Helix Proteins, Biomarkers, Tumor, Nerve Tissue Proteins.
Abstract (Originalsprache)
This study aims to explore the clinical significance of neuronal PAS domain protein 2 (NPAS2) in lung cancer, its relationship with the tumor immune microenvironment, and its potential upstream non-coding RNA (ncRNA) regulatory network. By analyzing transcriptomic data and clinical information from the Cancer Genome Atlas (TCGA) database, prognostic genes were identified, and NPAS2 expression was analyzed in lung adenocarcinoma and lung squamous cell carcinoma to determine its associations with patient survival and immune cell infiltration. Immunohistochemical analysis was also performed to compare NPAS2 expression between lung cancer tissues and adjacent non-tumor tissues. NPAS2 expression was elevated in tumor tissues, with higher expression associated with reduced overall survival. This association remained significant in multivariate Cox regression analysis (hazard ratio (HR) = 1.11687, P = 0.0252). In the analyzed dataset, a diagnostic model incorporating NPAS2, epidermal growth factor receptor (EGFR), marker of proliferation Ki-67 (MKI67), and tumor protein p63 (TP63) yielded an area under the receiver operating characteristic curve (AUC) of 0.987. Immune infiltration analysis revealed that in lung adenocarcinoma and lung squamous cell carcinoma, NPAS2 expression was positively correlated with CD4⁺ T cell and neutrophil infiltration, as well as with the expression of the immune checkpoint molecule sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15). Additionally, NPAS2 expression was positively correlated with the adenosine pathway markers CD39 and CD73. Bioinformatics analysis further identified a potential regulatory axis of NORAD/AC087477.2-hsa-miR-106a-5p/hsa-miR-17-5p-NPAS2. These results suggest that NPAS2 may be a candidate biomarker for lung cancer diagnosis and prognosis assessment and may be associated with tumor immune cell infiltration and adenosine-related immune regulatory processes. However, further functional experiments and clinical validation are needed to clarify its potential molecular mechanism and clinical application value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University; hayydaijj@njmu.edu.cn.
- Department of Pathology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University.
- Department of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University.
- Department of Pathology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University; hayyzhouwubi@njmu.edu.cn.
Zitieren
APA
Dai, J., Reyimu, A., Song, X., & Zhou, W. (2026). High Neuronal PAS Domain Protein 2 Expression Associated with Poor Prognosis, Tumor Immune Infiltration, and Adenosine Pathway Markers in Lung Cancer. Journal of Visualized Experiments. https://doi.org/10.3791/74928
Vancouver
Dai J, Reyimu A, Song X, Zhou W. High Neuronal PAS Domain Protein 2 Expression Associated with Poor Prognosis, Tumor Immune Infiltration, and Adenosine Pathway Markers in Lung Cancer. Journal of Visualized Experiments. 2026. doi:10.3791/74928
BibTeX
@article{Dai2026,
author = {Dai, Jingjing and Reyimu, Abdusemer and Song, Xudong and Zhou, Wubi},
title = {High Neuronal PAS Domain Protein 2 Expression Associated with Poor Prognosis, Tumor Immune Infiltration, and Adenosine Pathway Markers in Lung Cancer},
journal = {Journal of Visualized Experiments},
year = {2026},
number = {237},
doi = {10.3791/74928}
}
EUVIMED